Research

At Pharvis, we strive for a healthier and happier life for every family.

R&D pipeline

R&D 1

Project code Mode of action Indication Development stage
Discovery Preclinical Phase1 Phase2 Phase3 Approval
PA501
  • Leukotrien B4 receptor 2 inhibitor (BLT2 inhibitor)
 Severe asthma
Patent 1 Patent 2 Patent 3
Patent No.  :  10 - 1796391 Patenr No. : US 10,179,764 B2 Patent No.  :  10 - 1796390
Date of Patent : Nov. 3, 2017 Date of Patent : Jan. 15, 2019 Date of Patent : Nov. 3, 2017
Novel compound having BLT inhibitory activity and composition for preventing or treating inflammatory diseases, comprising same as active ingredient (Group 1, ethynyl) Compound having BLT inhibitory activity and composition, for preventing or treating inflammatory diseases, comprising same as active ingredient [Novel compound having BLT inhibitory activity and composition for preventing or treating inflammatory diseases, comprising same as active ingredient (Group 4, biphenyl)

R&D 2

Project code Mode of action Indication Development stage
Discovery Preclinical Phase1 Phase2 Phase3 Approval
PM601
  • GPR119 agonist
 NASH
Patent 1 Patent 2 Patent 3
Patent No. : 10 – 1665846 Patenr No. : US 9,895,370 B2 Patent No. : 10 - 1946516
Date of Patent : Sep. 6, 2016 Date of Patent : Feb. 20, 2018 Date of Patent : Jan. 31, 2019
Pharmaceutical composition for preventing or treating Of nonalcoholic fatty liver disease comprising G protein coupled receptor 119 ligand as an active ingredient Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient Pharmaceutical composition for preventing or treating of cirrhosis of liver comprising G protein coupled receptor 119 ligand as an active ingredient
TOP